UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)												
1. Name and Address of Reporting Person * BASS HERBERT B				2. Issuer Name and Ticker or Trading Symbol ENZO BIOCHEM INC [ENZ]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last) (First) (Middle) C/O ENZO BIOCHEM INC., 527 MADISON AVENUE				3. Date of Earliest Transaction (Month/Day/Year) 01/29/2010					X Officer (give title below) Other (specify below) Vice President of Finance					
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person _Form filed by More than One Reporting Person						
NEW YC	ORK, NY	(State)	(Zip)	T	able I - Non	-Der	ivative S	ecurities	Acan	ired Disne	nsed of or I	Reneficially (Owned	
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if	3. Transaction Code (Instr. 8)				uired of (D)	5. Amoun Beneficial	osed of, or Beneficially at of Securities lly Owned Following Transaction(s) and 4)		6. Ownership Form:	7. Nature of Indirect Beneficial Ownership	
				Code	V	Amount	(A) or (D)	Price				or Indirect (I (I) (Instr. 4)	(Instr. 4)	
Common Stock, par value \$0.01		01/29/2010		A 3,000 A (1) 165,112 (2)			D							
				Derivative Securit	ies Acquire	conta the f	ained in orm dis sposed o	this for plays a o	m are curre eficial	e not requently valid	OMB conf	spond unle	ss	1474 (9-02)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transactio Date (Month/Day/	n 3A. Deemed Execution Da any	te, if Transaction Code Year) (Instr. 8)	5.	6. Da and I (Mon	ate Exerc Expiration nth/Day/\footnote{\chi_0}	isable n Date Year)	7. T Ame Und Secu (Ins 4)	Amount or Number of	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownersh Form of Derivating Security Direct (I or Indire	Beneficia Ownershi (Instr. 4)
Repor	ting O	wners		Code V	(A) (D)					Shares				
				D 1 // 11				1						

D " O N /	Relationships						
Reporting Owner Name / Address	Director 10% Owner		Officer	Other			
BASS HERBERT B C/O ENZO BIOCHEM INC. 527 MADISON AVENUE NEW YORK, NY 10022			Vice President of Finance				

Signatures

/s/ Herbert B. Bass	02/02/2010			
**Signature of Reporting Person	Date			

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The Reporting Person was granted 3,000 shares of restricted common stock, par value \$0.01 per share ("Common Stock"), of the Company on January 29, 2010 in connection with his service as an officer of the Company. The shares will vest in three equal annual installments, beginning on January 29, 2011.
- (2) Includes 7,870 shares of Common Stock held in the Company's 401(k) plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.